N/A N=878 Pre-engraftment Cytomegalovirus DNAemia
CMV DNAemia Pre-engraftment
Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=160 Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
Acute Lung Injury · Acute Respiratory Distress Syndrome · Respiratory Failure
Primary: Serum IL-6 Level — -0.79; -0.79 pg/mL
N/A N=800 A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China
Cytomegalovirus (CMV) Infections Among Children and Adult Liver Transplantation Patients in China
Primary: Number of Participants With Clinically Significant CMV Reactivation or CMV Disease — 62; 89; 78; 32 Participants
Phase 4 N=40 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Number of Patients With Late CMV Disease — 0; 0 Participants
Phase 2 N=1 Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
Leukemia · Lymphoma
Primary: Number of Participants With Non-Relapse Mortality — 0 Participants
Phase 2 N=137 ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Transplantation Infection · Epstein-Barr Virus Infections · Cytomegalovirus Infections
Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants
Phase 4 N=30 Valganciclovir to Reduce T Cell Activation in HIV Infection
HIV Infections · Cytomegalovirus Infections
Primary: Change in %CD38+ Human Leukocyte Antigen-D-related (HLA-DR)+ CD8+ T Cells From Baseline to Week 8. — 1.3; -4.0 percentage of activated T cells
Phase 3 N=452 A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
CMV
Primary: Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant — 155; 78 Participants
N/A N=172 Dried Blood Spot Testing of CMV Detection in HCT Recipients
Cytomegalovirus Infection
Primary: The Number of Participants Who Have Completed >90% of Their Recommended Cytomegalovirus (CMV) Monitoring Tests in the DBS and Control Arms in the ITT Population — 27; 15…
Phase 2 N=10 Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Cytomegalovirus Infections
Primary: Virological Response on Treatment Week 6 — 5 Participants
Phase 2 N=58 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Cytomegalovirus
Primary: Number of Participants With a Complete Response — 8; 50 Participants
Phase 2 N=239 Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
Cytomegalovirus Infection
Primary: Number of Participants With Clinically Significant CMV Infection — 13; 4; 6; 4 Participants
Phase 3 N=96 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Cytomegalovirus Infection
Primary: Change in Best Ear Hearing Assessments at 6 Months. — 3; 5; 37; 36 participants
N/A N=14 An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients
Cytomegalovirus Infections
Primary: Proportion of Patients Developing Cytomegalovirus (CMV) Disease Within 6 Months of Liver Transplantation Under Valcyte Prophylaxis — 3 participants
Phase 3 N=514 A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Cytomegalovirus (CMV)-Positive Recipients · Allogeneic, Hematopoietic Cell Transplant (HCT)
Primary: Percentage of Participants With Composite of All-Cause Mortality and Adjudicated Cytomegalovirus End Organ Disease (CMV EOD) Through 1 Year Post Transplant — 30.20…
Phase 3 N=326 IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Cytomegalovirus Infections
Primary: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant — 43.6; 23.9 Percentage of patients — p=<=0.0002
Phase 2 N=131 Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients
HCMV Reactivation or HCMV End-Organ Disease
Primary: Number of Participants With "HCMV Prophylaxis Failure" — 16; 10; 10; 21 Participants — p=0.007
Phase 1 N=190 Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
Cytomegalovirus Infections
Primary: Percentage of Participants With an Adverse Event (AE) — 75.0; 92.9; 84.6; 100.0 Percentage of participants
Phase 2 N=77 Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
CMV Infection · Persistent CMV Viremia
Primary: Complete Response — 20; 57 Participants
N/A N=362 A Study in Adolescent Females to Explore Cytomegalovirus Infection
Infections, Cytomegalovirus
Primary: Number of CMV Seropositive Subjects With Appearance or Increase of Anti-CMV Tegument Protein IgG Antibodies in Serum. — 5; 2 Participants
Phase 3 N=601 Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
CMV Disease
Primary: Percentage of Participants With Adjudicated Cytomegalovirus (CMV) Disease Through 52 Weeks Post-transplant — 10.4; 11.8 Percentage of Participants
Phase 3 N=299 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Cytomegalovirus Infections
Primary: Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months — 14.1; 42.6 percentage of participants
Phase 2 N=4 ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Viral Infection
Primary: Number of Participants With a DLT — 0; 0; 0; 3 Participants
N/A N=111 Evaluation of the Artus® CMV PCR Test
Cytomegalovirus Infections
Primary: a) CMV Viral Load — 100; 97.6; 86.36; NA percentage of agreement
Phase 2 N=6 Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
B-Cell Prolymphocytic Leukemia · Chronic Lymphocytic Leukemia · Peripheral T-Cell Lymphoma
Primary: Cytomegalovirus (CMV) Reactivation
Phase 2 N=35 Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
Cytomegalovirus Infection
Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859
Phase 3 N=399 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Congenital Cytomegalovirus Infection · Maternal Cytomegalovirus Infection
Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42
Phase 4 N=236 Letermovir Use in Heart Transplant Recipients
Cytomegalovirus Disease · Cytomegalovirus Infections · Heart Transplant Infection
Primary: Proportion of Patients With Neutropenia Compared to Historical Controls — 0; 30 Participants — p=0.02
Phase 3 N=279 Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
HIV Infections · Acquired Immunodeficiency Syndrome · Cytomegalovirus Retinitis
Primary: Morbidity — 88; 93; 93 participants
Phase 2 N=83 A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
Cytomegalovirus (CMV) Infection · Kidney Transplantation
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 6; 3; 23; 12 Participants